BioSpace News Archive

Biorasi , a leading global, full-service contract research organization (CRO), is proud to announce the appointment of Jamie P. Dwyer, MD to the position of Scientific Advisory Board (SAB) member.

Moderna, Inc. today confirmed that following the European Medicines Agency’s (EMA) Committee for Human Medicines (CHMP) approval of the Recipharm Monts site on June 11, 2021, drug product manufacture of the Moderna COVID-19 vaccine at the site in France has now begun.

The awards, hosted annually by the Philadelphia Alliance for Capital and Technologies (PACT), celebrate innovation in science and technology in the Philadelphia region.

The cell line development market was valued at US$ 4,160.42 million in 2019 and is projected to reach US$ 11,219.87 million by 2027; it is expected to grow at a CAGR of 13.3% from 2020 to 2027.

The dental implants market was valued at US$ 3,872.3 million in 2018 and it is projected to reach US$ 7,417.4 million in 2027; it is expected to grow at a CAGR of 7.6% from 2019 to 2027.

Exacis today announced two significant advances in its manufacturing capabilities.

The Alzheimer’s Drug Discovery Foundation and Harrington Discovery Institute at University Hospitals in Cleveland have granted ADDF-Harrington Scholar Awards to two Principal Investigators, Paul Fish, Ph.D., of University College London’s Drug Discovery Institute and Paul Worley, M.D., of Johns Hopkins University.

POCARED announced that it has signed an agreement with GEM Global Yield LLC SCS, the Luxembourg based private alternative investment group to provide POCARED with up to $50 Million over a 36-month term following a public listing of POCARED’s common stock.

LG Chem announced topline results for the phase 2 study evaluating the efficacy and safety profiles of LC350189, a novel non-purine xanthine oxidase inhibitor for the chronic management of hyperuricemia in patients with gout disease.

mRNA Victoria, the agency of the Australian State of Victoria Government charged with building the State’s mRNA manufacturing and research capability announced that a locally-developed COVID vaccine candidate will enter Phase 1 clinical trials in October, 2021.